Money and Molecules: Early-Stage Life Science Financing

March 30, 2017

Early-stage life science companies face a complex and challenging financing environment; even for the virtual life science startups of today, the cost to bring a candidate molecule even to clinical trials is daunting. Yet the number of traditional venture capital firms investing in life sciences has continued to shrink, and several of the remaining serious investors pursue a different model of investing in their own incubated startups. Strategic partners can provide non-dilutive capital and significant other resources but are guided and constrained by corporate strategy that must align with the target's technology and strategy. Government grants are still available, but the volume had fallen dramatically even before the unpredictable direction of the Trump administration. There has also been an increase in investments from new classes of investors recently, including family offices, super angels, and foreign funds. So how does a young life science company form its financing strategy?

Join us to hear a panel of experts discuss these trends. Discover, among other things, how they:

- Formulate a comprehensive and coherent financing strategy
- Construct a financing strategy that fits the company's timetable and milestones
- Understand and handle the disadvantages of taking money from different investor types
- Understand and leverage the advantages of different classes of investors
- Optimize their chances for success

Moderator:
John Hession, Partner, *Morse*

Panel:
Jeffrey M. Arnold, President & CEO, *Arnold Strategies, LLC*
Timothy E. Sullivan, Partner, *Aju IB Investment*
John Tagliamonte, Advisory Board, *Cocoon Biotech*
Caleb M. Winder, Managing Director, *Excel Venture Management*

This is a complimentary event, but seating is limited.